ArticleFrontiers in cardiovascular medicine2022
Case report: Transplantation of human induced pluripotent stem cell-derived cardiomyocyte patches for ischemic cardiomyopathy.
Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Quality control and non-clinical testing of iPSC- and ESC-derived medicinal products: A systematic review.Stem cell reports · 2026Pooled it
- Induced pluripotent stem cell therapies in heart failure treatment: a meta-analysis and systematic review.Regenerative medicinePooled it
- Impact of secretome containing extracellular vesicles from human induced pluripotent stem cell-derived cardiomyocytes.Regenerative therapy · 2026Article
- Human induced pluripotent stem cell-derived cardiomyocyte patch enhances cardiac regeneration in a J2N-k hamster model of dilated cardiomyopathy.Regenerative therapy · 2026Article
- Induced pluripotent stem cells from discovery to translation.Nature medicine · 2026Review
- Review
- Biofabrication strategies for engineered constructs in cardiovascular tissue repair.Regenerative therapy · 2026Review
- Engineered cardiac patches from hiPSC-derived cardiomyocytes.Stem cell research & therapy · 2026Review
- Nanomicelle-Based Multi-mRNA Delivery Promotes Cardiac Repair After Myocardial Infarction.Small science · 2026Article
- The road to restore male fertility using in vitro-derived germ cells.Human reproduction update · 2026Review
- Intravenous high mobility group box 1 fragment improves cardiac function, fibrosis, and coronary flow in porcine ischemic cardiomyopathy model.Scientific reports · 2026Article
- Bioengineered Cellular and Acellular Therapies for Ischemic Heart Disease in Clinically Relevant Models.Bioengineering (Basel, Switzerland) · 2026Review
- Dabigatran and Edoxaban in the Repair of an Abnormal Cleft in the Right Wall of the Ascending Aorta: A Case Report.Cureus · 2026Article
- Progress and challenges in transplantation of human pluripotent stem cell derived cardiomyocytes for cardiac therapy.npj biomedical innovations · 2026Review
- Human iPSC-derived cardiac-specific extracellular matrix scaffolds for cardiomyocyte maturation and post-myocardial infarction repair.Bioactive materials · 2026Article
- Heart Regeneration for Clinical Application.Internal medicine (Tokyo, Japan) · 2026Review
- Human iPSCs derived from cryopreserved testicular somatic cells enable germline regeneration in childhood cancer survivors.Human reproduction open · 2026Article
- Scaffold-free cell sheet therapies: clinical advances, global approval landscapes, and strategic directions to address regenerative medicine barriers.Stem cell research & therapy · 2025Review
- Cellular senescence and cell therapy in cardiovascular diseases.Stem cell research & therapy · 2025Review
- Human induced pluripotent stem cell-derived cardiomyocytes improve recovery from myocardial infarction in non-human primates.Stem cell research & therapy · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite major therapeutic advances, heart failure, as a non-communicable disease, remains a life-threatening disorder, with 26 million patients worldwide, causing more deaths than cancer. Therefore, novel strategies for the treatment of heart failure continue to be an important clinical need. Based on preclinical studies, allogenic human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) patches have been proposed as a potential therapeutic candidate for heart failure. We report the implantation of allogeneic hiPSC-CM patches in a patient with ischemic cardiomyopathy (ClinicalTrials.gov, #jRCT2053190081). The patches were produced under clinical-grade conditions and displayed cardiogenic phenotypes and safety
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.